Q Fever 市場 - 2018-2028 年全球產業規模、佔有率、趨勢、機會和預測，按類型、藥物類型、最終用戶、地區、競爭細分

2022 年，全球 Q Fever 市場價值為 486 萬美元，預計在預測期內將強勁成長，到 2028 年CAGR為 4.21%。Q Fever 也稱為查詢熱。它是一種由伯氏柯克斯體細菌引起的細菌感染。引起這種發燒的細菌存在於全球牛、綿羊和山羊等動物體內。許多患者根本沒有任何症狀，而在某些情況下；感染可能在數年後再次發生。慢性 Q 熱是 Q 熱的一種毒性更強的形式，可能會損害心臟、大腦、肺部，在某些情況下可能導致糖尿病。根據美國疾病管制與預防中心（CDC）發布的資料，2019年美國報告了178例急性Q熱病例和34例慢性Q熱病例。根據國家醫學圖書館發布的報告(NLM) 到2020 年，每年10萬人中約有50 人患有急性Q 熱，而一年中100 萬人中就有1 人患有慢性Q 熱。此外，務農、免疫力低下、老年人等人也更容易罹患Q熱。

主要市場促進因素

發病率增加

市場概況
預測期	2024-2028
2022 年市場規模	48.6億美元
2028 年市場規模	62.2億美元
2023-2028 年CAGR	4.21%
成長最快的細分市場	醫院
最大的市場	北美洲

由於全球 Q 熱發生率不斷上升，全球 Q 熱市場可望顯著成長。這種由伯氏立克次體細菌引起的傳染病的報告病例顯著增加，推動了對診斷工具、治療方式和預防措施的需求。發病率上升可歸因於多種因素，包括認知的提高、診斷能力的提高以及有利於病原體擴散的環境模式的改變。隨著 Q 熱的流行激增，製藥公司、診斷實驗室和醫療保健提供者可能會看到對其產品和服務的需求增加。策略合作、研發計劃以及對先進技術的投資將進一步推動市場的擴張，以實現準確和及時的診斷。此外，政府和醫療機構預計將加強控制和管理 Q 熱的傳播，從而獲得監管支持和有利的報銷方案。總之，在發病率不斷上升的推動下，全球 Q 熱市場將經歷強勁成長，為整個醫療保健領域的利害關係人創造利潤豐厚的機會。市場發展的特點是創新、戰略合作夥伴關係以及積極應對 Q 熱帶來的日益嚴峻的公共衛生挑戰。

目錄

第 1 章：產品概述

• 市場定義
• 市場範圍
  • 涵蓋的市場
  • 研究年份
  • 主要市場區隔

第 2 章：研究方法

• 研究目的
• 基線方法
• 主要產業夥伴
• 主要協會和二手資料來源
• 預測方法
• 數據三角測量與驗證
• 假設和限制

第 3 章：執行摘要

• 市場概況
• 主要市場細分概述
• 主要市場參與者概述
• 重點地區/國家概況
• 市場促進因素、挑戰、趨勢概述

第 4 章：客戶之聲

第 5 章：全球 Q Fever 市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 依類型（急性 Q 熱、慢性 Q 熱）
  • 依藥物類型（抗生素、抗瘧藥、皮質類固醇、其他）
  • 最終使用者（醫院、診所、研究所）
  • 按地區（北美、歐洲、亞太地區、南美、中東和非洲）
  • 按公司分類 (2022)
• 市場地圖
  • 按類型
  • 依藥物類型
  • 由最終用戶
  • 按地區

第 6 章：北美 Q Fever 市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 按類型（急性、慢性）
  • 依藥物類型（抗生素、抗瘧藥、皮質類固醇、其他）
  • 最終使用者（醫院、診所、研究所）
  • 按國家/地區
• 北美：國家分析
  • 美國
  • 加拿大
  • 墨西哥

第 7 章：歐洲 Q Fever 市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 按類型（急性、慢性）
  • 依藥物類型（抗生素、抗瘧藥、皮質類固醇、其他）
  • 最終使用者（醫院、診所、研究所）
  • 按國家/地區
• 歐洲：國家分析
  • 法國
  • 德國
  • 英國
  • 義大利
  • 西班牙

第 8 章：亞太地區 Q Fever 市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 按類型（急性、慢性）
  • 依藥物類型（抗生素、抗瘧藥、皮質類固醇、其他）
  • 最終使用者（醫院、診所、研究所）
  • 按國家/地區
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第 9 章：南美洲 Q Fever 市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 按類型（急性、慢性）
  • 依藥物類型（抗生素、抗瘧藥、皮質類固醇、其他）
  • 最終使用者（醫院、診所、研究所）
  • 按國家/地區
• 南美洲：國家分析
  • 巴西
  • 阿根廷
  • 哥倫比亞

第 10 章：中東和非洲 Q Fever 市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 依類型（急性 Q 熱、慢性 Q 熱）
  • 依藥物類型（抗生素、抗瘧藥、皮質類固醇、其他）
  • 最終使用者（醫院、診所、研究所）
  • 按國家/地區
• MEA：國家分析
  • 南非 Q 熱
  • 沙烏地阿拉伯 Q 熱
  • 阿拉伯聯合大公國 Q 熱

第 11 章：市場動態

• 促進要素
• 挑戰

第 12 章：市場趨勢與發展

• 近期發展
• 併購
• 產品發布

第 13 章：全球 Q Fever 市場：SWOT 分析

第 14 章：波特的五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的力量
• 客戶的力量
• 替代產品的威脅

第15章：競爭格局

• 太陽製藥工業有限公司
  • Business Overview
  • Product Offerings
  • Recent Developments
  • Financials (As Reported)
  • Key Personnel
  • SWOT Analysis
• 雅培實驗室公司
• 奧羅賓多製藥有限公司。
• 輝瑞公司
• 盧平有限公司。
• 拜耳公司
• 諾華製藥公司
• 葛蘭素史克公司
• 默克公司，
• 賽諾菲公司。

第 16 章：策略建議

Global Q Fever Market has valued at USD 4.86 Million in 2022 and is anticipated to project robust growth in the forecast period with a CAGR of 4.21% through 2028. Q fever is also known as the query fever. It is a type of bacterial infection which is caused by the Coxiella burnetiid bacteria. The bacteria which is causing this fever are found in animals such as cattle, sheep, and goats globally. Many of the patients witness no symptoms at all while in some cases; the infection can reoccur years later. The chronic Q fever is a more toxic form of Q fever that may damage heart, brain, lungs and can cause diabetes in some cases. As per the data released by the Centers for Disease Control and Prevention (CDC), in 2019, 178 cases of acute Q fever, and 34 cases of chronic Q fever were stated in the U.S. According to the report published by the National Library of Medicine (NLM) in 2020, around 50 people out of 100,000 suffer from acute Q fever yearly while 1 person out of 1,000,000 suffers from chronic Q fever in one year. Additionally, people having farmworkers, low immunity, and old age people are more possibly to get Q fever.

Key Market Drivers

Increasing Incidence Rates

Market Overview
Forecast Period	2024-2028
Market Size 2022	USD 4.86 Billion
Market Size 2028	USD 6.22 Billion
CAGR 2023-2028	4.21%
Fastest Growing Segment	Hospitals
Largest Market	North America

The Global Q Fever Market is poised for significant growth owing to the escalating incidence rates of Q fever worldwide. This infectious disease, caused by the bacterium Coxiella burnetii, has witnessed a notable uptick in reported cases, propelling the demand for diagnostic tools, treatment modalities, and preventive measures. The rising incidence can be attributed to various factors, including increased awareness, improved diagnostic capabilities, and changing environmental patterns that favor the proliferation of the causative agent. As the prevalence of Q fever surges, pharmaceutical companies, diagnostic laboratories, and healthcare providers are likely to witness a heightened demand for their products and services. The market's expansion will be further fueled by strategic collaborations, research and development initiatives, and investments in advanced technologies for accurate and timely diagnosis. Furthermore, governments and healthcare organizations are expected to intensify efforts to control and manage the spread of Q fever, leading to regulatory support and favorable reimbursement scenarios. In conclusion, the Global Q Fever Market is set to experience robust growth driven by the mounting incidence rates, creating lucrative opportunities for stakeholders across the healthcare spectrum. The market's evolution will be characterized by innovation, strategic partnerships, and a proactive response to the increasing public health challenge posed by Q fever.

Rising Awareness and Education

The Global Q Fever Market is poised for substantial growth as awareness and education regarding Q fever intensify globally. Increased efforts in educating healthcare professionals, policymakers, and the general public about the risks, symptoms, and preventive measures associated with Q fever are likely to drive early detection and treatment. This heightened awareness is expected to result in a surge in demand for diagnostic tools, pharmaceuticals, and vaccines, fueling the expansion of the Q fever market. Rising awareness also plays a pivotal role in fostering research and development activities, encouraging investments in innovative solutions for Q fever diagnosis and treatment. As healthcare stakeholders become more informed about the impact of Q fever on public health, there is a growing emphasis on preventive strategies and effective management protocols. This, in turn, creates a conducive environment for market growth, with pharmaceutical companies and healthcare institutions actively contributing to the development of advanced therapeutic and diagnostic options.

Animal Husbandry Practices

The growth of the Global Q Fever Market is intricately linked to evolving animal husbandry practices worldwide. As Q fever is primarily a zoonotic disease, its prevalence is closely tied to livestock management. Modernization and intensification of animal husbandry practices contribute to the increased transmission risk of Coxiella burnetii, the causative agent of Q fever. Larger livestock populations, close human-animal interactions, and the global movement of animals enhance the potential for transmission. As the scale and complexity of animal farming operations continue to expand, there is a growing need for effective diagnostic tools, vaccines, and treatment options within the Q fever market. Proactive management strategies, including vaccination programs and biosecurity measures in animal husbandry, become essential components in mitigating the spread of Q fever. Consequently, businesses engaged in the development and provision of veterinary healthcare products are poised for significant market growth.

Key Market Challenges

Underdiagnosis and Misdiagnosis

Underdiagnosis and misdiagnosis pose substantial obstacles to the growth of the Global Q Fever Market. The nuanced clinical presentation of Q fever, often mimicking other common illnesses, contributes to its under recognition by healthcare professionals. This diagnostic challenge leads to delayed or inaccurate identification of cases, hindering the timely initiation of appropriate treatment. As a consequence, the demand for Q fever-specific diagnostic tools, therapies, and preventive measures may be underestimated, impeding market growth. The lack of standardized diagnostic protocols and the variability in clinical manifestations contribute to misdiagnosis, further complicating the accurate assessment of Q fever prevalence. Inaccurate diagnoses may result in inappropriate treatments and inefficient resource allocation, affecting both patient outcomes and the overall market landscape. Healthcare providers and pharmaceutical companies face the challenge of addressing these diagnostic gaps through increased awareness campaigns, medical education, and the development of more accurate and accessible diagnostic technologies.

Vaccine Development Challenges

Vaccine development challenges present significant barriers to the growth of the Global Q Fever Market. The inherently complex nature of the Coxiella burnetii bacterium, the causative agent of Q fever, poses obstacles to the development of a universally effective vaccine. Variability in strains, the bacterium's ability to evade the host immune response, and the absence of well-defined correlates of protection contribute to the difficulty in formulating a robust Q fever vaccine. The lengthy and resource-intensive nature of vaccine development, coupled with uncertainties surrounding regulatory approval, further compounds these challenges. High research and development costs, coupled with the need for extensive clinical trials, can deter pharmaceutical companies from investing in Q fever vaccine development. This hesitancy may limit the availability of preventive measures, hindering market growth. Moreover, the limited commercial appeal of Q fever vaccines, given the relatively low prevalence of the disease compared to other infectious agents, may result in a lack of incentive for companies to undertake vaccine development. Overcoming these challenges necessitates collaborative efforts between public and private sectors, research institutions, and regulatory bodies to incentivize and facilitate the development of effective Q fever vaccines, ultimately unlocking the growth potential of the Global Q Fever Market.

Key Market Trends

Technological Advancements in Diagnostics

Technological advancements in diagnostics are poised to catalyze the growth of the Global Q Fever Market. Innovations in diagnostic technologies, such as molecular diagnostics, serological assays, and point-of-care testing, enable more accurate and rapid detection of Coxiella burnetii, the bacterium causing Q fever. Enhanced sensitivity and specificity of diagnostic tools contribute to early and precise identification of cases, facilitating prompt initiation of treatment and containment measures. Automation and integration of diagnostic processes streamline testing procedures, reducing turnaround times and increasing testing efficiency. These advancements not only improve patient outcomes but also drive demand for sophisticated diagnostic solutions, fostering market growth. Additionally, the integration of artificial intelligence (AI) and machine learning algorithms in diagnostic platforms enhances the interpretative capabilities, allowing for more nuanced and data-driven diagnostic insights. The adoption of these cutting-edge diagnostic technologies is expected to be a key driver in the expansion of the Q Fever Market. As healthcare providers and laboratories increasingly embrace advanced diagnostic tools, there is a corresponding rise in the demand for state-of-the-art solutions, creating opportunities for businesses in the diagnostic sector to thrive and contribute to the evolving landscape of Q fever management on a global scale.

Focus on Vaccine Development

The intensified focus on vaccine development is poised to propel the growth of the Global Q Fever Market. As the pharmaceutical industry dedicates increased resources to address public health challenges, the development of an effective Q fever vaccine has become a strategic priority. The potential for a preventive vaccine not only signifies a breakthrough in managing the infectious disease but also opens up significant market opportunities. The prospect of a Q fever vaccine stimulates investment in research and development, attracting pharmaceutical companies to enter the market and participate in the race for a viable solution. Government initiatives, regulatory support, and global health organizations further incentivize vaccine development, fostering a conducive environment for market growth. A successful Q fever vaccine holds the promise of reducing the prevalence and severity of the disease, driving demand and uptake across diverse demographics. This focus on preventive measures aligns with broader healthcare trends, positioning vaccine developers at the forefront of addressing global health challenges. Consequently, the Global Q Fever Market stands to benefit from heightened attention to vaccine development, with potential positive impacts on public health outcomes and business opportunities within the pharmaceutical sector.

Segmental Insights

Type Insights

Based on the Type, the Acute Q Fever segment is anticipated to witness substantial market growth throughout the forecast period. The prominence of Acute Q Fever is anticipated to be a pivotal driver in propelling the growth of the Global Q Fever Market. As the acute form of the disease garners increased recognition, healthcare providers and pharmaceutical companies are likely to witness a surge in demand for diagnostic tools, treatment options, and preventive measures. Acute Q Fever, characterized by sudden onset and a range of symptoms, necessitates prompt and accurate diagnosis, creating a robust market demand for advanced diagnostic technologies. The urgency in managing acute cases also emphasizes the need for effective therapeutic interventions, spurring pharmaceutical companies to invest in research and development to meet this demand. Additionally, the heightened awareness surrounding Acute Q Fever is expected to drive public and private sector initiatives, encouraging collaborations and strategic partnerships within the healthcare industry. The market's growth is further fueled by the potential for innovations in pharmaceuticals and diagnostic solutions tailored to address the acute phase of Q fever. As healthcare systems globally prioritize rapid and comprehensive responses to infectious diseases, the emphasis on Acute Q Fever is positioned to significantly contribute to the expansion of the Global Q Fever Market.

End-Users Insights

Based on the End-Users segment, the Hospitals segment has been the dominant force in the market. Hospitals are poised to play a pivotal role in driving the growth of the Global Q Fever Market. The increasing incidence of Q fever underscores the central role of healthcare institutions, particularly hospitals, in managing and treating affected individuals. As Q fever cases are diagnosed and treated primarily within hospital settings, there is a heightened demand for advanced diagnostic tools, therapeutic interventions, and specialized care units. Hospitals are key stakeholders in the market ecosystem, driving the adoption of cutting-edge diagnostic technologies for timely and accurate Q fever detection. The emphasis on creating dedicated units for infectious disease management within hospitals further amplifies the market's growth potential. Pharmaceutical companies, in turn, collaborate with hospitals to develop and provide effective treatments, fostering a symbiotic relationship that drives innovation and market expansion. Moreover, hospitals act as focal points for public health initiatives, contributing to awareness campaigns, preventive measures, and collaborative research efforts. As healthcare providers increasingly prioritize infectious disease management, hospitals are positioned as catalysts for growth in the Global Q Fever Market, shaping the trajectory of the market through their pivotal roles in diagnosis, treatment, and public health advocacy.

Regional Insights

North America, specifically the Q Fever Market, dominated the market in 2022, primarily due to The North America region is poised to be a significant driver of growth in the Global Q Fever Market. With a well-established healthcare infrastructure and advanced diagnostic capabilities, North America is at the forefront of Q fever management. The region's proactive approach to infectious diseases, coupled with robust research and development initiatives, positions it as a key contributor to the market's expansion. Increasing awareness among healthcare professionals and the general public about Q fever, its symptoms, and preventive measures is fostering early detection and diagnosis. This, in turn, amplifies the demand for diagnostic tools, pharmaceuticals, and vaccines within the region. Additionally, strategic collaborations between pharmaceutical companies, research institutions, and healthcare organizations contribute to the development of innovative solutions, driving market growth. Government support and stringent regulatory frameworks further propel the market by incentivizing investments in Q fever-related research and product development. As North America takes a leadership role in addressing public health challenges, the region emerges as a pivotal driver in shaping the trajectory of the Global Q Fever Market, offering both business opportunities and improved healthcare outcomes.

Key Market Players

Sun Pharmaceutical Industries Ltd.

Abbott Laboratories Inc.

Aurobindo Pharma Limited.

Pfizer Inc.

Lupin Limited.

Bayer AG

Novartis Pharmaceuticals Corporation

GSK plc.

Merck & Co., Inc.,

Sanofi SA.

Report Scope:

In this report, the Global Q Fever Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Q Fever Market, By Type:

• Acute Q Fever
• Chronic Q Fever

Q Fever Market, By Medication Type:

• Antibiotics
• Antimalerial
• Corticosteroids
• Others

Q Fever Market, By End-Users:

• Hospitals
• Clinics
• Research Institutes

Q Fever Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia-Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• Kuwait
• Turkey
• Egypt

Competitive Landscape

• Company Profiles: Detailed analysis of the major companies present in the Global Q Fever Market.

Available Customizations:

• Global Q Fever market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Q Fever Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Acute Q Fever, Chronic Q Fever)
  • 5.2.2. By Medication Type (Antibiotics, Antimalerial, Corticosteroids, Others)
  • 5.2.3. By End-Users (Hospitals, Clinics, Research Institutes)
  • 5.2.4. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
  • 5.2.5. By Company (2022)
• 5.3. Market Map
  • 5.3.1 By Type
  • 5.3.2 By Medication Type
  • 5.3.3 By End-Users
  • 5.3.4 By Region

6. North America Q Fever Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type (Acute Q Fever, Chronic Q Fever)
  • 6.2.2. By Medication Type (Antibiotics, Antimalerial, Corticosteroids, Others)
  • 6.2.3. By End-Users (Hospitals, Clinics, Research Institutes)
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Q Fever Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Medication Type
      • 6.3.1.2.3. By End-Users
  • 6.3.2. Canada Q Fever Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Medication Type
      • 6.3.2.2.3. By End-Users
  • 6.3.3. Mexico Q Fever Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Medication Type
      • 6.3.3.2.3. By End-Users

7. Europe Q Fever Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type (Acute Q Fever, Chronic Q Fever)
  • 7.2.2. By Medication Type (Antibiotics, Antimalerial, Corticosteroids, Others)
  • 7.2.3. By End-Users (Hospitals, Clinics, Research Institutes)
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Q Fever Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Medication Type
      • 7.3.1.2.3. By End-Users
  • 7.3.2. Germany Q Fever Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Medication Type
      • 7.3.2.2.3. By End-Users
  • 7.3.3. United Kingdom Q Fever Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Medication Type
      • 7.3.3.2.3. By End-Users
  • 7.3.4. Italy Q Fever Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Medication Type
      • 7.3.4.2.3. By End-Users
  • 7.3.5. Spain Q Fever Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Medication Type
      • 7.3.5.2.3. By End-Users

8. Asia-Pacific Q Fever Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type (Acute Q Fever, Chronic Q Fever)
  • 8.2.2. By Medication Type (Antibiotics, Antimalerial, Corticosteroids, Others)
  • 8.2.3. By End-Users (Hospitals, Clinics, Research Institutes)
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Q Fever Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Medication Type
      • 8.3.1.2.3. By End-Users
  • 8.3.2. India Q Fever Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Medication Type
      • 8.3.2.2.3. By End-Users
  • 8.3.3. Japan Q Fever Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Medication Type
      • 8.3.3.2.3. By End-Users
  • 8.3.4. South Korea Q Fever Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Medication Type
      • 8.3.4.2.3. By End-Users
  • 8.3.5. Australia Q Fever Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Medication Type
      • 8.3.5.2.3. By End-Users

9. South America Q Fever Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type (Acute Q Fever, Chronic Q Fever)
  • 9.2.2. By Medication Type (Antibiotics, Antimalerial, Corticosteroids, Others)
  • 9.2.3. By End-Users (Hospitals, Clinics, Research Institutes)
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Q Fever Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Medication Type
      • 9.3.1.2.3. By End-Users
  • 9.3.2. Argentina Q Fever Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Medication Type
      • 9.3.2.2.3. By End-Users
  • 9.3.3. Colombia Q Fever Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Medication Type
      • 9.3.3.2.3. By End-Users

10. Middle East and Africa Q Fever Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type (Acute Q Fever, Chronic Q Fever)
  • 10.2.2. By Medication Type (Antibiotics, Antimalerial, Corticosteroids, Others)
  • 10.2.3. By End-Users (Hospitals, Clinics, Research Institutes)
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Q Fever Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Medication Type
      • 10.3.1.2.3. By End-Users
  • 10.3.2. Saudi Arabia Q Fever Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Medication Type
      • 10.3.2.2.3. By End-Users
  • 10.3.3. UAE Q Fever Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Medication Type
      • 10.3.3.2.3. By End-Users

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Global Q Fever Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Sun Pharmaceutical Industries Ltd.
  • 15.1.1. Business Overview
  • 15.1.2. Product Offerings
  • 15.1.3. Recent Developments
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Key Personnel
  • 15.1.6. SWOT Analysis
• 15.2. Abbott Laboratories Inc.
• 15.3. Aurobindo Pharma Limited.
• 15.4. Pfizer Inc.
• 15.5. Lupin Limited.
• 15.6. Bayer AG
• 15.7. Novartis Pharmaceuticals Corporation
• 15.8. GSK plc.
• 15.9. Merck & Co., Inc.,
• 15.10. Sanofi SA.

16. Strategic Recommendations